Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2018
UK ‘less interesting’ to pharma because of Brexit – Roche CEO
14 September 2018 - The UK could be “less interesting” to pharma and life sciences firms after Brexit, the CEO ...
Posted by Michael Wonder on 13 Sep 2018
Can a cancer drug originated in China be a success in the U.S.?
13 September 2018 - While China has prospered in a variety of technologies over the last decade, one area where growth ...
Posted by Michael Wonder on 13 Sep 2018
BIO, Allergan and Roche call for FDA flexibility with patient experience data
13 September 2018 - Industry group BIO and biopharma companies Allergan and Roche are calling for the FDA to be ...
Posted by Michael Wonder on 11 Sep 2018
Health secretary’s ‘rip off’ remarks anger UK pharma
11 September 2018 - Row with Vertex has tainted government-industry relations. ...
Posted by Michael Wonder on 10 Sep 2018
Drug firms try to rip off taxpayers, says Matt Hancock
8 September 2018 - Pharmaceutical companies are trying to “rip off taxpayers” and big business must be more socially responsible, ...
Posted by Michael Wonder on 06 Sep 2018
Hospitals are fed up with drug companies, so they’re starting their own
6 September 2018 - A group of major American hospitals, battered by price spikes on old drugs and long-lasting shortages ...
Posted by Michael Wonder on 05 Sep 2018
Statement from FDA Commissioner on the agency’s global efforts to help assure product quality and transparency at foreign drug manufacturing facilities
5 September 2018 - Over the past 25 years, globalisation of drug manufacturing has prompted the FDA to change its ...
Posted by Michael Wonder on 04 Sep 2018
China is sprucing up its pharma sector
30 August 2018 - The changes are helping multinational drugmakers. In time they may boost the domestic industry. ...
Posted by Michael Wonder on 29 Aug 2018
FDA pushes for development of non-opioid pain medications
29 August 2018 - The FDA is planning new steps to encourage the development of nonaddictive alternatives to opioid pain ...
Posted by Michael Wonder on 28 Aug 2018
Pfizer calls for FDA guidance to address false and misleading biosimilar advertisements
28 August 2018 - Taking issue with Amgen, Genentech and other reference product sponsors’ dissemination of misleading information on biosimilars, ...
Posted by Michael Wonder on 23 Aug 2018
FDA adds four tropical diseases to priority review voucher program to encourage drug development in areas of unmet need
23 August 2018 - Today, the U.S. FDA announced the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis ...
Posted by Michael Wonder on 20 Aug 2018
Companies report no signs of drug makers cutting prices, despite Trump pledge
17 August 2018 - Several companies that manage prescription drug benefits for insurers say they have not received any commitments ...
Posted by Michael Wonder on 19 Aug 2018
States rush to rein in prescription costs, and drug companies fight back
18 August 2018 - States around the country are clamping down on pharmaceutical companies, forcing them to disclose and justify ...
Posted by Michael Wonder on 18 Aug 2018
CVS’s drug price plan lets pharma off too easy
18 August 2018 - A new program aimed at keeping costs down allows too many expensive treatments to slip through. ...
Posted by Michael Wonder on 01 Aug 2018
FDA supports critical research to spur innovation for continuous manufacturing technology to support and advance drug and biologics development
1 August 2018 - We know that novel manufacturing technologies for both small-molecule drugs and biological products have great potential to ...